nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—psoriatic arthritis	0.54	1	CbGaD
Thalidomide—PTGS2—Triamcinolone—psoriatic arthritis	0.0593	0.246	CbGbCtD
Thalidomide—PTGS2—Betamethasone—psoriatic arthritis	0.0509	0.211	CbGbCtD
Thalidomide—PTGS2—Dexamethasone—psoriatic arthritis	0.0296	0.123	CbGbCtD
Thalidomide—CYP1A1—Dexamethasone—psoriatic arthritis	0.025	0.104	CbGbCtD
Thalidomide—CYP2C19—Prednisone—psoriatic arthritis	0.0194	0.0806	CbGbCtD
Thalidomide—CYP2E1—Dexamethasone—psoriatic arthritis	0.0193	0.0802	CbGbCtD
Thalidomide—CYP3A5—Dexamethasone—psoriatic arthritis	0.015	0.0623	CbGbCtD
Thalidomide—CYP2C19—Dexamethasone—psoriatic arthritis	0.0121	0.0503	CbGbCtD
Thalidomide—CYP2C9—Dexamethasone—psoriatic arthritis	0.0101	0.0418	CbGbCtD
Thalidomide—NFKB1—IL17 signaling pathway—TRAF3IP2—psoriatic arthritis	0.00393	0.047	CbGpPWpGaD
Thalidomide—Pomalidomide—TNF—psoriatic arthritis	0.00371	1	CrCbGaD
Thalidomide—NFKB1—Inflammasomes—MEFV—psoriatic arthritis	0.0036	0.043	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—CARD14—psoriatic arthritis	0.00338	0.0404	CbGpPWpGaD
Thalidomide—NFKB1—Atypical NF-kappaB pathway—REL—psoriatic arthritis	0.00266	0.0318	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL23R—psoriatic arthritis	0.00259	0.0309	CbGpPWpGaD
Thalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—CARD14—psoriatic arthritis	0.00257	0.0308	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL23A—psoriatic arthritis	0.0022	0.0263	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL23R—psoriatic arthritis	0.00197	0.0235	CbGpPWpGaD
Thalidomide—NFKB1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—MEFV—psoriatic arthritis	0.00173	0.0207	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL23A—psoriatic arthritis	0.00168	0.02	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL15—psoriatic arthritis	0.00156	0.0186	CbGpPWpGaD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—NOD2—psoriatic arthritis	0.00121	0.0145	CbGpPWpGaD
Thalidomide—NFKB1—IL17 signaling pathway—IL17A—psoriatic arthritis	0.00119	0.0142	CbGpPWpGaD
Thalidomide—NFKB1—TAK1 activates NFkB by phosphorylation and activation of IKKs complex—NOD2—psoriatic arthritis	0.0011	0.0131	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL13—psoriatic arthritis	0.0011	0.0131	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—LTA—psoriatic arthritis	0.00104	0.0125	CbGpPWpGaD
Thalidomide—TNF—IL27-mediated signaling events—IL17A—psoriatic arthritis	0.00104	0.0124	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL17A—psoriatic arthritis	0.00103	0.0123	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNFRSF1B—psoriatic arthritis	0.000971	0.0116	CbGpPWpGaD
Thalidomide—TNF—IL27-mediated signaling events—IL12B—psoriatic arthritis	0.000967	0.0116	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL12B—psoriatic arthritis	0.000957	0.0114	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL12B—psoriatic arthritis	0.000939	0.0112	CbGpPWpGaD
Thalidomide—TNF—Canonical NF-kappaB pathway—NOD2—psoriatic arthritis	0.000923	0.011	CbGpPWpGaD
Thalidomide—NFKB1—IL-1 signaling pathway—REL—psoriatic arthritis	0.000891	0.0106	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—LTA—psoriatic arthritis	0.000795	0.0095	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL17A—psoriatic arthritis	0.000785	0.00938	CbGpPWpGaD
Thalidomide—NFKB1—Activation of NF-kappaB in B cells—REL—psoriatic arthritis	0.00078	0.00931	CbGpPWpGaD
Thalidomide—NFKB1—Interleukin-1 signaling—NOD2—psoriatic arthritis	0.000778	0.0093	CbGpPWpGaD
Thalidomide—TNF—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000764	0.00913	CbGpPWpGaD
Thalidomide—TNF—TNF receptor signaling pathway —TNFRSF1B—psoriatic arthritis	0.00074	0.00884	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL12B—psoriatic arthritis	0.000729	0.00872	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—REL—psoriatic arthritis	0.000695	0.00831	CbGpPWpGaD
Thalidomide—NFKB1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD2—psoriatic arthritis	0.000651	0.00778	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—IL12B—psoriatic arthritis	0.00065	0.00777	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000613	0.00732	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—REL—psoriatic arthritis	0.000601	0.00718	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNFRSF1B—psoriatic arthritis	0.0006	0.00716	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000595	0.00711	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—IL13—psoriatic arthritis	0.000592	0.00707	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.00059	0.00705	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000566	0.00676	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.000562	0.00672	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.000558	0.00666	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—HLA-DRB1—psoriatic arthritis	0.000553	0.0066	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—NOS2—psoriatic arthritis	0.000537	0.00641	CbGpPWpGaD
Thalidomide—NFKB1—Downstream TCR signaling—HLA-DRB1—psoriatic arthritis	0.000519	0.0062	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000506	0.00604	CbGpPWpGaD
Thalidomide—PTGS2—Fluocinonide—Methylprednisolone—psoriatic arthritis	0.000489	0.159	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Dexamethasone—psoriatic arthritis	0.000481	0.156	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Betamethasone—psoriatic arthritis	0.000481	0.156	CbGdCrCtD
Thalidomide—PTGS2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000473	0.00565	CbGpPWpGaD
Thalidomide—NFKB1—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000471	0.00562	CbGpPWpGaD
Thalidomide—PTGS2—Fluocinonide—Triamcinolone—psoriatic arthritis	0.00047	0.153	CbGdCrCtD
Thalidomide—TNF—Allograft Rejection—HLA-C—psoriatic arthritis	0.000468	0.00559	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL13—psoriatic arthritis	0.000465	0.00555	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TNFRSF1B—psoriatic arthritis	0.000457	0.00546	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—CRP—psoriatic arthritis	0.000455	0.00544	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.00045	0.00537	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL17A—psoriatic arthritis	0.000428	0.00511	CbGpPWpGaD
Thalidomide—NFKB1—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000426	0.00509	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000425	0.00508	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.000425	0.00508	CbGpPWpGaD
Thalidomide—NFKB1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000422	0.00504	CbGpPWpGaD
Thalidomide—NFKB1—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000414	0.00495	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—NOS2—psoriatic arthritis	0.000409	0.00489	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.0004	0.00477	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL12B—psoriatic arthritis	0.000398	0.00475	CbGpPWpGaD
Thalidomide—NFKB1—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000393	0.00469	CbGpPWpGaD
Thalidomide—NFKB1—EBV LMP1 signaling—TNF—psoriatic arthritis	0.00039	0.00466	CbGpPWpGaD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—TNF—psoriatic arthritis	0.00039	0.00466	CbGpPWpGaD
Thalidomide—NFKB1—TCR signaling—HLA-DRB1—psoriatic arthritis	0.000388	0.00464	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000383	0.00457	CbGpPWpGaD
Thalidomide—NFKB1—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000377	0.0045	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—CRP—psoriatic arthritis	0.00037	0.00443	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000366	0.00438	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—NOS2—psoriatic arthritis	0.000365	0.00436	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	0.000354	0.00423	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000351	0.0042	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000348	0.00415	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—CRP—psoriatic arthritis	0.000347	0.00414	CbGpPWpGaD
Thalidomide—NFKB1—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000339	0.00405	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000338	0.00404	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000336	0.00402	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.000334	0.00399	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000332	0.00397	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000324	0.00387	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—REL—psoriatic arthritis	0.000324	0.00387	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000319	0.00381	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—REL—psoriatic arthritis	0.000307	0.00367	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-C—psoriatic arthritis	0.000305	0.00365	CbGpPWpGaD
Thalidomide—NFKB1—amb2 Integrin signaling—TNF—psoriatic arthritis	0.000299	0.00358	CbGpPWpGaD
Thalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.000295	0.0958	CbGdCrCtD
Thalidomide—NFKB1—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000294	0.00352	CbGpPWpGaD
Thalidomide—NFKB1—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—psoriatic arthritis	0.000292	0.00349	CbGpPWpGaD
Thalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.00029	0.0943	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.00029	0.0943	CbGdCrCtD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000284	0.00339	CbGpPWpGaD
Thalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000284	0.0921	CbGdCrCtD
Thalidomide—TNF—Folate Metabolism—CRP—psoriatic arthritis	0.000282	0.00337	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-B—psoriatic arthritis	0.000277	0.0033	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	0.00027	0.00322	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.00027	0.00322	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—TNF—psoriatic arthritis	0.000266	0.00318	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.000264	0.00316	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000253	0.00302	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MEFV—psoriatic arthritis	0.000244	0.00292	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000241	0.00288	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000234	0.0028	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MEFV—psoriatic arthritis	0.000232	0.00277	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000224	0.00268	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000224	0.00267	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNF—psoriatic arthritis	0.000224	0.00267	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000223	0.00266	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—TNF—psoriatic arthritis	0.000216	0.00259	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000214	0.00256	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000214	0.00256	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	0.000209	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—TNF—psoriatic arthritis	0.000206	0.00246	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—psoriatic arthritis	0.0002	0.00239	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TNF—psoriatic arthritis	0.000197	0.00235	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000194	0.00232	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000184	0.0022	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-B—psoriatic arthritis	0.000181	0.00216	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000175	0.00209	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—psoriatic arthritis	0.000168	0.002	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000164	0.00196	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000162	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—psoriatic arthritis	0.00016	0.00191	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—psoriatic arthritis	0.000148	0.00177	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MEFV—psoriatic arthritis	0.000142	0.0017	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000139	0.00166	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000138	0.00165	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—psoriatic arthritis	0.000138	0.00165	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MEFV—psoriatic arthritis	0.000135	0.00161	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—psoriatic arthritis	0.000133	0.00159	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000132	0.00158	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000131	0.00157	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—REL—psoriatic arthritis	0.00013	0.00156	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000129	0.00154	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HLA-C—psoriatic arthritis	0.000125	0.00149	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—REL—psoriatic arthritis	0.000124	0.00148	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.00012	0.00144	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HLA-C—psoriatic arthritis	0.000119	0.00142	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000118	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000114	0.00136	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000112	0.00133	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000105	0.00126	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—NOS2—psoriatic arthritis	0.0001	0.00119	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	9.87e-05	0.00118	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	9.36e-05	0.00112	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	9.36e-05	0.00112	CbGpPWpGaD
Thalidomide—Sweating—Methotrexate—psoriatic arthritis	9.29e-05	0.000724	CcSEcCtD
Thalidomide—Infection—Methylprednisolone—psoriatic arthritis	9.28e-05	0.000723	CcSEcCtD
Thalidomide—Haematuria—Methotrexate—psoriatic arthritis	9.24e-05	0.00072	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	9.24e-05	0.0011	CbGpPWpGaD
Thalidomide—Shock—Triamcinolone—psoriatic arthritis	9.21e-05	0.000717	CcSEcCtD
Thalidomide—Insomnia—Prednisolone—psoriatic arthritis	9.21e-05	0.000717	CcSEcCtD
Thalidomide—Alopecia—Prednisone—psoriatic arthritis	9.2e-05	0.000716	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—NOD2—psoriatic arthritis	9.2e-05	0.0011	CbGpPWpGaD
Thalidomide—Shock—Methylprednisolone—psoriatic arthritis	9.19e-05	0.000716	CcSEcCtD
Thalidomide—Nervous system disorder—Methylprednisolone—psoriatic arthritis	9.16e-05	0.000713	CcSEcCtD
Thalidomide—Loss of consciousness—Betamethasone—psoriatic arthritis	9.15e-05	0.000712	CcSEcCtD
Thalidomide—Loss of consciousness—Dexamethasone—psoriatic arthritis	9.15e-05	0.000712	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—psoriatic arthritis	9.14e-05	0.000712	CcSEcCtD
Thalidomide—Paraesthesia—Prednisolone—psoriatic arthritis	9.14e-05	0.000712	CcSEcCtD
Thalidomide—Tachycardia—Triamcinolone—psoriatic arthritis	9.14e-05	0.000711	CcSEcCtD
Thalidomide—Mental disorder—Prednisone—psoriatic arthritis	9.12e-05	0.00071	CcSEcCtD
Thalidomide—Tachycardia—Methylprednisolone—psoriatic arthritis	9.12e-05	0.00071	CcSEcCtD
Thalidomide—Skin disorder—Methylprednisolone—psoriatic arthritis	9.07e-05	0.000707	CcSEcCtD
Thalidomide—Malnutrition—Prednisone—psoriatic arthritis	9.07e-05	0.000706	CcSEcCtD
Thalidomide—Hyperhidrosis—Triamcinolone—psoriatic arthritis	9.05e-05	0.000705	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—psoriatic arthritis	9.05e-05	0.000704	CcSEcCtD
Thalidomide—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	9.03e-05	0.000703	CcSEcCtD
Thalidomide—Convulsion—Dexamethasone—psoriatic arthritis	9.02e-05	0.000702	CcSEcCtD
Thalidomide—Convulsion—Betamethasone—psoriatic arthritis	9.02e-05	0.000702	CcSEcCtD
Thalidomide—Hypertension—Betamethasone—psoriatic arthritis	8.99e-05	0.0007	CcSEcCtD
Thalidomide—Hypertension—Dexamethasone—psoriatic arthritis	8.99e-05	0.0007	CcSEcCtD
Thalidomide—Myalgia—Betamethasone—psoriatic arthritis	8.86e-05	0.00069	CcSEcCtD
Thalidomide—Myalgia—Dexamethasone—psoriatic arthritis	8.86e-05	0.00069	CcSEcCtD
Thalidomide—Anxiety—Dexamethasone—psoriatic arthritis	8.83e-05	0.000688	CcSEcCtD
Thalidomide—Anxiety—Betamethasone—psoriatic arthritis	8.83e-05	0.000688	CcSEcCtD
Thalidomide—Discomfort—Betamethasone—psoriatic arthritis	8.76e-05	0.000682	CcSEcCtD
Thalidomide—Discomfort—Dexamethasone—psoriatic arthritis	8.76e-05	0.000682	CcSEcCtD
Thalidomide—Hypotension—Methylprednisolone—psoriatic arthritis	8.73e-05	0.00068	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—NOD2—psoriatic arthritis	8.73e-05	0.00104	CbGpPWpGaD
Thalidomide—Pain—Prednisolone—psoriatic arthritis	8.71e-05	0.000678	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—psoriatic arthritis	8.7e-05	0.000678	CcSEcCtD
Thalidomide—Pharyngitis—Methotrexate—psoriatic arthritis	8.64e-05	0.000673	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—psoriatic arthritis	8.6e-05	0.000669	CcSEcCtD
Thalidomide—Vision blurred—Prednisone—psoriatic arthritis	8.54e-05	0.000665	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—psoriatic arthritis	8.53e-05	0.000664	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	8.53e-05	0.000664	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	8.51e-05	0.000663	CcSEcCtD
Thalidomide—Oedema—Dexamethasone—psoriatic arthritis	8.5e-05	0.000661	CcSEcCtD
Thalidomide—Oedema—Betamethasone—psoriatic arthritis	8.5e-05	0.000661	CcSEcCtD
Thalidomide—Insomnia—Triamcinolone—psoriatic arthritis	8.47e-05	0.000659	CcSEcCtD
Thalidomide—Insomnia—Methylprednisolone—psoriatic arthritis	8.45e-05	0.000658	CcSEcCtD
Thalidomide—Infection—Dexamethasone—psoriatic arthritis	8.44e-05	0.000657	CcSEcCtD
Thalidomide—Infection—Betamethasone—psoriatic arthritis	8.44e-05	0.000657	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	8.43e-05	0.00101	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Prednisone—psoriatic arthritis	8.41e-05	0.000655	CcSEcCtD
Thalidomide—Paraesthesia—Triamcinolone—psoriatic arthritis	8.41e-05	0.000655	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisolone—psoriatic arthritis	8.39e-05	0.000653	CcSEcCtD
Thalidomide—Paraesthesia—Methylprednisolone—psoriatic arthritis	8.39e-05	0.000653	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—psoriatic arthritis	8.39e-05	0.000653	CcSEcCtD
Thalidomide—Anaemia—Prednisone—psoriatic arthritis	8.38e-05	0.000652	CcSEcCtD
Thalidomide—Shock—Betamethasone—psoriatic arthritis	8.36e-05	0.000651	CcSEcCtD
Thalidomide—Shock—Dexamethasone—psoriatic arthritis	8.36e-05	0.000651	CcSEcCtD
Thalidomide—Dyspnoea—Triamcinolone—psoriatic arthritis	8.35e-05	0.00065	CcSEcCtD
Thalidomide—Nervous system disorder—Dexamethasone—psoriatic arthritis	8.33e-05	0.000649	CcSEcCtD
Thalidomide—Nervous system disorder—Betamethasone—psoriatic arthritis	8.33e-05	0.000649	CcSEcCtD
Thalidomide—Agitation—Prednisone—psoriatic arthritis	8.33e-05	0.000649	CcSEcCtD
Thalidomide—Thrombocytopenia—Betamethasone—psoriatic arthritis	8.32e-05	0.000648	CcSEcCtD
Thalidomide—Thrombocytopenia—Dexamethasone—psoriatic arthritis	8.32e-05	0.000648	CcSEcCtD
Thalidomide—Tachycardia—Dexamethasone—psoriatic arthritis	8.29e-05	0.000646	CcSEcCtD
Thalidomide—Tachycardia—Betamethasone—psoriatic arthritis	8.29e-05	0.000646	CcSEcCtD
Thalidomide—Angioedema—Prednisone—psoriatic arthritis	8.28e-05	0.000645	CcSEcCtD
Thalidomide—Dyspepsia—Triamcinolone—psoriatic arthritis	8.24e-05	0.000642	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—psoriatic arthritis	8.23e-05	0.000641	CcSEcCtD
Thalidomide—Dyspepsia—Methylprednisolone—psoriatic arthritis	8.22e-05	0.00064	CcSEcCtD
Thalidomide—Hyperhidrosis—Dexamethasone—psoriatic arthritis	8.21e-05	0.000639	CcSEcCtD
Thalidomide—Hyperhidrosis—Betamethasone—psoriatic arthritis	8.21e-05	0.000639	CcSEcCtD
Thalidomide—Malaise—Prednisone—psoriatic arthritis	8.18e-05	0.000636	CcSEcCtD
Thalidomide—Vertigo—Prednisone—psoriatic arthritis	8.14e-05	0.000634	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—psoriatic arthritis	8.13e-05	0.000633	CcSEcCtD
Thalidomide—Syncope—Prednisone—psoriatic arthritis	8.13e-05	0.000633	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—psoriatic arthritis	8.11e-05	0.000632	CcSEcCtD
Thalidomide—Anorexia—Dexamethasone—psoriatic arthritis	8.1e-05	0.000631	CcSEcCtD
Thalidomide—Anorexia—Betamethasone—psoriatic arthritis	8.1e-05	0.000631	CcSEcCtD
Thalidomide—Urticaria—Prednisolone—psoriatic arthritis	8.09e-05	0.00063	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—psoriatic arthritis	8.08e-05	0.000629	CcSEcCtD
Thalidomide—Fatigue—Triamcinolone—psoriatic arthritis	8.07e-05	0.000629	CcSEcCtD
Thalidomide—Fatigue—Methylprednisolone—psoriatic arthritis	8.05e-05	0.000627	CcSEcCtD
Thalidomide—Pain—Triamcinolone—psoriatic arthritis	8.01e-05	0.000623	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisone—psoriatic arthritis	7.97e-05	0.00062	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—psoriatic arthritis	7.94e-05	0.000949	CbGpPWpGaD
Thalidomide—Hypotension—Betamethasone—psoriatic arthritis	7.94e-05	0.000618	CcSEcCtD
Thalidomide—Hypotension—Dexamethasone—psoriatic arthritis	7.94e-05	0.000618	CcSEcCtD
Thalidomide—NFKB1—Immune System—REL—psoriatic arthritis	7.92e-05	0.000946	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—psoriatic arthritis	7.91e-05	0.000945	CbGpPWpGaD
Thalidomide—Angiopathy—Methotrexate—psoriatic arthritis	7.9e-05	0.000615	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—psoriatic arthritis	7.86e-05	0.000612	CcSEcCtD
Thalidomide—Convulsion—Prednisone—psoriatic arthritis	7.85e-05	0.000612	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—psoriatic arthritis	7.84e-05	0.000611	CcSEcCtD
Thalidomide—Hypertension—Prednisone—psoriatic arthritis	7.83e-05	0.000609	CcSEcCtD
Thalidomide—Chills—Methotrexate—psoriatic arthritis	7.81e-05	0.000608	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	7.74e-05	0.000603	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	7.74e-05	0.000603	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—psoriatic arthritis	7.72e-05	0.000601	CcSEcCtD
Thalidomide—Myalgia—Prednisone—psoriatic arthritis	7.72e-05	0.000601	CcSEcCtD
Thalidomide—Feeling abnormal—Triamcinolone—psoriatic arthritis	7.72e-05	0.000601	CcSEcCtD
Thalidomide—Feeling abnormal—Methylprednisolone—psoriatic arthritis	7.7e-05	0.000599	CcSEcCtD
Thalidomide—Anxiety—Prednisone—psoriatic arthritis	7.69e-05	0.000599	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—psoriatic arthritis	7.69e-05	0.000599	CcSEcCtD
Thalidomide—Insomnia—Betamethasone—psoriatic arthritis	7.68e-05	0.000598	CcSEcCtD
Thalidomide—Insomnia—Dexamethasone—psoriatic arthritis	7.68e-05	0.000598	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	7.66e-05	0.000597	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	7.64e-05	0.000595	CcSEcCtD
Thalidomide—Paraesthesia—Betamethasone—psoriatic arthritis	7.63e-05	0.000594	CcSEcCtD
Thalidomide—Paraesthesia—Dexamethasone—psoriatic arthritis	7.63e-05	0.000594	CcSEcCtD
Thalidomide—Discomfort—Prednisone—psoriatic arthritis	7.63e-05	0.000594	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—psoriatic arthritis	7.63e-05	0.000594	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—psoriatic arthritis	7.58e-05	0.00059	CcSEcCtD
Thalidomide—FGFR2—Immune System—REL—psoriatic arthritis	7.51e-05	0.000897	CbGpPWpGaD
Thalidomide—Hypersensitivity—Prednisolone—psoriatic arthritis	7.5e-05	0.000584	CcSEcCtD
Thalidomide—Dyspepsia—Dexamethasone—psoriatic arthritis	7.48e-05	0.000582	CcSEcCtD
Thalidomide—Dyspepsia—Betamethasone—psoriatic arthritis	7.48e-05	0.000582	CcSEcCtD
Thalidomide—Urticaria—Triamcinolone—psoriatic arthritis	7.44e-05	0.000579	CcSEcCtD
Thalidomide—Urticaria—Methylprednisolone—psoriatic arthritis	7.42e-05	0.000578	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—psoriatic arthritis	7.42e-05	0.000578	CcSEcCtD
Thalidomide—Body temperature increased—Triamcinolone—psoriatic arthritis	7.4e-05	0.000576	CcSEcCtD
Thalidomide—Oedema—Prednisone—psoriatic arthritis	7.4e-05	0.000576	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—HLA-B—psoriatic arthritis	7.4e-05	0.000884	CbGpPWpGaD
Thalidomide—Abdominal pain—Methylprednisolone—psoriatic arthritis	7.39e-05	0.000575	CcSEcCtD
Thalidomide—Decreased appetite—Dexamethasone—psoriatic arthritis	7.39e-05	0.000575	CcSEcCtD
Thalidomide—Decreased appetite—Betamethasone—psoriatic arthritis	7.39e-05	0.000575	CcSEcCtD
Thalidomide—Infection—Prednisone—psoriatic arthritis	7.35e-05	0.000572	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	7.33e-05	0.000571	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	7.33e-05	0.000571	CcSEcCtD
Thalidomide—Back pain—Methotrexate—psoriatic arthritis	7.33e-05	0.000571	CcSEcCtD
Thalidomide—Fatigue—Dexamethasone—psoriatic arthritis	7.32e-05	0.00057	CcSEcCtD
Thalidomide—Fatigue—Betamethasone—psoriatic arthritis	7.32e-05	0.00057	CcSEcCtD
Thalidomide—NFKB1—Immune System—HLA-C—psoriatic arthritis	7.28e-05	0.00087	CbGpPWpGaD
Thalidomide—Shock—Prednisone—psoriatic arthritis	7.28e-05	0.000567	CcSEcCtD
Thalidomide—Pain—Betamethasone—psoriatic arthritis	7.27e-05	0.000566	CcSEcCtD
Thalidomide—Pain—Dexamethasone—psoriatic arthritis	7.27e-05	0.000566	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—psoriatic arthritis	7.26e-05	0.000565	CcSEcCtD
Thalidomide—Tachycardia—Prednisone—psoriatic arthritis	7.22e-05	0.000562	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—psoriatic arthritis	7.19e-05	0.00056	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	7.17e-05	0.000856	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Prednisone—psoriatic arthritis	7.15e-05	0.000557	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—psoriatic arthritis	7.14e-05	0.000556	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-B—psoriatic arthritis	7.1e-05	0.000849	CbGpPWpGaD
Thalidomide—Anorexia—Prednisone—psoriatic arthritis	7.05e-05	0.000549	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—psoriatic arthritis	7.03e-05	0.000547	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—HLA-B—psoriatic arthritis	7.02e-05	0.000838	CbGpPWpGaD
Thalidomide—Anaemia—Methotrexate—psoriatic arthritis	7e-05	0.000545	CcSEcCtD
Thalidomide—Feeling abnormal—Dexamethasone—psoriatic arthritis	7e-05	0.000545	CcSEcCtD
Thalidomide—Feeling abnormal—Betamethasone—psoriatic arthritis	7e-05	0.000545	CcSEcCtD
Thalidomide—Gastrointestinal pain—Betamethasone—psoriatic arthritis	6.95e-05	0.000541	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	6.95e-05	0.000541	CcSEcCtD
Thalidomide—FGFR2—Immune System—HLA-C—psoriatic arthritis	6.91e-05	0.000826	CbGpPWpGaD
Thalidomide—Hypersensitivity—Triamcinolone—psoriatic arthritis	6.9e-05	0.000537	CcSEcCtD
Thalidomide—Hypersensitivity—Methylprednisolone—psoriatic arthritis	6.88e-05	0.000536	CcSEcCtD
Thalidomide—Malaise—Methotrexate—psoriatic arthritis	6.83e-05	0.000532	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—psoriatic arthritis	6.81e-05	0.00053	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—psoriatic arthritis	6.78e-05	0.000528	CcSEcCtD
Thalidomide—Urticaria—Dexamethasone—psoriatic arthritis	6.75e-05	0.000525	CcSEcCtD
Thalidomide—Urticaria—Betamethasone—psoriatic arthritis	6.75e-05	0.000525	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	6.74e-05	0.000525	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—HLA-B—psoriatic arthritis	6.74e-05	0.000805	CbGpPWpGaD
Thalidomide—Dizziness—Prednisolone—psoriatic arthritis	6.73e-05	0.000524	CcSEcCtD
Thalidomide—Asthenia—Triamcinolone—psoriatic arthritis	6.72e-05	0.000523	CcSEcCtD
Thalidomide—Body temperature increased—Betamethasone—psoriatic arthritis	6.72e-05	0.000523	CcSEcCtD
Thalidomide—Body temperature increased—Dexamethasone—psoriatic arthritis	6.72e-05	0.000523	CcSEcCtD
Thalidomide—Abdominal pain—Betamethasone—psoriatic arthritis	6.72e-05	0.000523	CcSEcCtD
Thalidomide—Abdominal pain—Dexamethasone—psoriatic arthritis	6.72e-05	0.000523	CcSEcCtD
Thalidomide—Asthenia—Methylprednisolone—psoriatic arthritis	6.7e-05	0.000522	CcSEcCtD
Thalidomide—Insomnia—Prednisone—psoriatic arthritis	6.69e-05	0.000521	CcSEcCtD
Thalidomide—Paraesthesia—Prednisone—psoriatic arthritis	6.64e-05	0.000517	CcSEcCtD
Thalidomide—Pruritus—Triamcinolone—psoriatic arthritis	6.62e-05	0.000516	CcSEcCtD
Thalidomide—Cough—Methotrexate—psoriatic arthritis	6.61e-05	0.000515	CcSEcCtD
Thalidomide—Pruritus—Methylprednisolone—psoriatic arthritis	6.61e-05	0.000515	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—psoriatic arthritis	6.56e-05	0.000511	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—CRP—psoriatic arthritis	6.54e-05	0.000781	CbGpPWpGaD
Thalidomide—Dyspepsia—Prednisone—psoriatic arthritis	6.51e-05	0.000507	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—psoriatic arthritis	6.45e-05	0.000502	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—psoriatic arthritis	6.45e-05	0.000502	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—psoriatic arthritis	6.45e-05	0.000502	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—psoriatic arthritis	6.43e-05	0.000501	CcSEcCtD
Thalidomide—Rash—Prednisolone—psoriatic arthritis	6.42e-05	0.0005	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—psoriatic arthritis	6.41e-05	0.000499	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	6.41e-05	0.000499	CcSEcCtD
Thalidomide—Diarrhoea—Methylprednisolone—psoriatic arthritis	6.39e-05	0.000498	CcSEcCtD
Thalidomide—Fatigue—Prednisone—psoriatic arthritis	6.38e-05	0.000497	CcSEcCtD
Thalidomide—Headache—Prednisolone—psoriatic arthritis	6.38e-05	0.000497	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—psoriatic arthritis	6.37e-05	0.000496	CcSEcCtD
Thalidomide—Constipation—Prednisone—psoriatic arthritis	6.33e-05	0.000493	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—psoriatic arthritis	6.28e-05	0.00075	CbGpPWpGaD
Thalidomide—Confusional state—Methotrexate—psoriatic arthritis	6.23e-05	0.000485	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—CRP—psoriatic arthritis	6.2e-05	0.000741	CbGpPWpGaD
Thalidomide—Dizziness—Triamcinolone—psoriatic arthritis	6.19e-05	0.000482	CcSEcCtD
Thalidomide—Dizziness—Methylprednisolone—psoriatic arthritis	6.18e-05	0.000481	CcSEcCtD
Thalidomide—Infection—Methotrexate—psoriatic arthritis	6.14e-05	0.000478	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisone—psoriatic arthritis	6.1e-05	0.000475	CcSEcCtD
Thalidomide—Asthenia—Dexamethasone—psoriatic arthritis	6.1e-05	0.000475	CcSEcCtD
Thalidomide—Asthenia—Betamethasone—psoriatic arthritis	6.1e-05	0.000475	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—psoriatic arthritis	6.06e-05	0.000472	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—psoriatic arthritis	6.05e-05	0.000471	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—psoriatic arthritis	6.05e-05	0.000471	CcSEcCtD
Thalidomide—Nausea—Prednisolone—psoriatic arthritis	6.05e-05	0.000471	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.01e-05	0.000718	CbGpPWpGaD
Thalidomide—Pruritus—Dexamethasone—psoriatic arthritis	6.01e-05	0.000468	CcSEcCtD
Thalidomide—Pruritus—Betamethasone—psoriatic arthritis	6.01e-05	0.000468	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—psoriatic arthritis	6.01e-05	0.000468	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—psoriatic arthritis	5.98e-05	0.000465	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	5.97e-05	0.000713	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	5.97e-05	0.000713	CbGpPWpGaD
Thalidomide—Vomiting—Triamcinolone—psoriatic arthritis	5.95e-05	0.000464	CcSEcCtD
Thalidomide—Vomiting—Methylprednisolone—psoriatic arthritis	5.94e-05	0.000462	CcSEcCtD
Thalidomide—Rash—Triamcinolone—psoriatic arthritis	5.9e-05	0.00046	CcSEcCtD
Thalidomide—Dermatitis—Triamcinolone—psoriatic arthritis	5.9e-05	0.000459	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—psoriatic arthritis	5.89e-05	0.000459	CcSEcCtD
Thalidomide—Rash—Methylprednisolone—psoriatic arthritis	5.89e-05	0.000459	CcSEcCtD
Thalidomide—Dermatitis—Methylprednisolone—psoriatic arthritis	5.89e-05	0.000458	CcSEcCtD
Thalidomide—Urticaria—Prednisone—psoriatic arthritis	5.88e-05	0.000458	CcSEcCtD
Thalidomide—Headache—Triamcinolone—psoriatic arthritis	5.87e-05	0.000457	CcSEcCtD
Thalidomide—Headache—Methylprednisolone—psoriatic arthritis	5.85e-05	0.000456	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—psoriatic arthritis	5.85e-05	0.000455	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—psoriatic arthritis	5.85e-05	0.000455	CcSEcCtD
Thalidomide—Diarrhoea—Betamethasone—psoriatic arthritis	5.81e-05	0.000453	CcSEcCtD
Thalidomide—Diarrhoea—Dexamethasone—psoriatic arthritis	5.81e-05	0.000453	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—psoriatic arthritis	5.78e-05	0.00045	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	5.7e-05	0.000682	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	5.63e-05	0.000439	CcSEcCtD
Thalidomide—Dizziness—Dexamethasone—psoriatic arthritis	5.62e-05	0.000437	CcSEcCtD
Thalidomide—Dizziness—Betamethasone—psoriatic arthritis	5.62e-05	0.000437	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—psoriatic arthritis	5.59e-05	0.000435	CcSEcCtD
Thalidomide—Nausea—Triamcinolone—psoriatic arthritis	5.56e-05	0.000433	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—psoriatic arthritis	5.55e-05	0.000432	CcSEcCtD
Thalidomide—Nausea—Methylprednisolone—psoriatic arthritis	5.55e-05	0.000432	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—psoriatic arthritis	5.51e-05	0.000429	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—psoriatic arthritis	5.5e-05	0.000428	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—psoriatic arthritis	5.45e-05	0.000424	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—psoriatic arthritis	5.44e-05	0.000424	CcSEcCtD
Thalidomide—Vomiting—Betamethasone—psoriatic arthritis	5.4e-05	0.000421	CcSEcCtD
Thalidomide—Vomiting—Dexamethasone—psoriatic arthritis	5.4e-05	0.000421	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—psoriatic arthritis	5.38e-05	0.000418	CcSEcCtD
Thalidomide—NFKB1—Immune System—NOD2—psoriatic arthritis	5.36e-05	0.00064	CbGpPWpGaD
Thalidomide—Rash—Dexamethasone—psoriatic arthritis	5.36e-05	0.000417	CcSEcCtD
Thalidomide—Rash—Betamethasone—psoriatic arthritis	5.36e-05	0.000417	CcSEcCtD
Thalidomide—Dermatitis—Betamethasone—psoriatic arthritis	5.35e-05	0.000417	CcSEcCtD
Thalidomide—Dermatitis—Dexamethasone—psoriatic arthritis	5.35e-05	0.000417	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	5.34e-05	0.000416	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—psoriatic arthritis	5.33e-05	0.000415	CcSEcCtD
Thalidomide—Headache—Betamethasone—psoriatic arthritis	5.32e-05	0.000414	CcSEcCtD
Thalidomide—Headache—Dexamethasone—psoriatic arthritis	5.32e-05	0.000414	CcSEcCtD
Thalidomide—Asthenia—Prednisone—psoriatic arthritis	5.31e-05	0.000413	CcSEcCtD
Thalidomide—Pain—Methotrexate—psoriatic arthritis	5.29e-05	0.000412	CcSEcCtD
Thalidomide—Pruritus—Prednisone—psoriatic arthritis	5.23e-05	0.000408	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—psoriatic arthritis	5.1e-05	0.000397	CcSEcCtD
Thalidomide—FGFR2—Immune System—NOD2—psoriatic arthritis	5.08e-05	0.000607	CbGpPWpGaD
Thalidomide—Diarrhoea—Prednisone—psoriatic arthritis	5.06e-05	0.000394	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—psoriatic arthritis	5.06e-05	0.000394	CcSEcCtD
Thalidomide—Nausea—Dexamethasone—psoriatic arthritis	5.05e-05	0.000393	CcSEcCtD
Thalidomide—Nausea—Betamethasone—psoriatic arthritis	5.05e-05	0.000393	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—psoriatic arthritis	4.96e-05	0.000593	CbGpPWpGaD
Thalidomide—Urticaria—Methotrexate—psoriatic arthritis	4.91e-05	0.000382	CcSEcCtD
Thalidomide—Dizziness—Prednisone—psoriatic arthritis	4.89e-05	0.000381	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—psoriatic arthritis	4.89e-05	0.000381	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—psoriatic arthritis	4.89e-05	0.000381	CcSEcCtD
Thalidomide—Vomiting—Prednisone—psoriatic arthritis	4.7e-05	0.000366	CcSEcCtD
Thalidomide—Rash—Prednisone—psoriatic arthritis	4.67e-05	0.000363	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—psoriatic arthritis	4.66e-05	0.000363	CcSEcCtD
Thalidomide—Headache—Prednisone—psoriatic arthritis	4.64e-05	0.000361	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—psoriatic arthritis	4.56e-05	0.000355	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—psoriatic arthritis	4.44e-05	0.000345	CcSEcCtD
Thalidomide—Nausea—Prednisone—psoriatic arthritis	4.39e-05	0.000342	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—psoriatic arthritis	4.37e-05	0.000341	CcSEcCtD
Thalidomide—NFKB1—Immune System—HLA-B—psoriatic arthritis	4.31e-05	0.000515	CbGpPWpGaD
Thalidomide—Diarrhoea—Methotrexate—psoriatic arthritis	4.23e-05	0.000329	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—psoriatic arthritis	4.09e-05	0.000318	CcSEcCtD
Thalidomide—FGFR2—Immune System—HLA-B—psoriatic arthritis	4.09e-05	0.000488	CbGpPWpGaD
Thalidomide—Vomiting—Methotrexate—psoriatic arthritis	3.93e-05	0.000306	CcSEcCtD
Thalidomide—Rash—Methotrexate—psoriatic arthritis	3.9e-05	0.000304	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—psoriatic arthritis	3.9e-05	0.000303	CcSEcCtD
Thalidomide—Headache—Methotrexate—psoriatic arthritis	3.87e-05	0.000302	CcSEcCtD
Thalidomide—NFKB1—Immune System—CRP—psoriatic arthritis	3.81e-05	0.000455	CbGpPWpGaD
Thalidomide—Nausea—Methotrexate—psoriatic arthritis	3.67e-05	0.000286	CcSEcCtD
Thalidomide—NFKB1—Immune System—HLA-DRB1—psoriatic arthritis	3.65e-05	0.000436	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—psoriatic arthritis	3.61e-05	0.000432	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—psoriatic arthritis	3.46e-05	0.000413	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.38e-05	0.000403	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—psoriatic arthritis	3.35e-05	0.0004	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—psoriatic arthritis	3.04e-05	0.000363	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—psoriatic arthritis	1.51e-05	0.00018	CbGpPWpGaD
